NS
Therapeutic Areas
Amneal Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Brekiya (dihydroergotamine mesylate) | Acute Treatment of Migraine & Cluster Headache | Approved |
| CREXONT (Carbidopa/Levodopa) | Parkinson's Disease | Approved |
| Mesalamine DR | Gastroenterology (Ulcerative Colitis) | Approved |
| Everolimus | Oncology | Approved |
| Epinephrine (Adrenalin generic) | Emergency/Critical Care | Pending Approval |
| Prednisolone acetate | Ophthalmology | Approved |
| Risperidone ER | Psychiatry | Approved |
| Iohexol (Omnipaque generic) | Diagnostic Imaging | Pending Approval |
Leadership Team at Amneal Pharmaceuticals
CP
Chirag Patel
President and Co-Chief Executive Officer, Co-Founder
CP
Chintu Patel
Co-Chief Executive Officer, Co-Founder
TK
Tasos Konidaris
Executive Vice President, Chief Financial Officer
JB
Jason B. Daly, Esq.
Executive Vice President, Chief Legal Officer & Corporate Secretary
GS
Gregory Sgammato
Senior Vice President, Corporate Development
AS
Andrew S. Boyer
Executive Vice President, Chief Commercial Officer – Generics & Biosciences
JR
Joe Renda
Senior Vice President, Chief Commercial Officer - Specialty
UK
Upendra Kumar Singh
President, India Business and Emerging Markets
SK
Srinivas Kone, PhD
Senior Vice President, Chief Scientific Officer – Generics
AD
Avinash Desai, MD
Senior Vice President, Chief Scientific Officer – Specialty